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The main objectives of this study were (a) to evaluate the in vitro performance of the rapid disintegration tablets as a way to
improve the solid dispersions and (b) to study the in vivo pharmacokinetics of the albendazole modified formulation in dogs. Rapid
disintegration of tablets seems to be a key factor for efficiency of solid dispersions with regard to improvement of the albendazole
bioavailability. The in vivo assays performed on dogs showed a marked increase in drug plasma exposure when albendazole was
given in solid dispersions incorporated into rapid disintegration tablets compared with conventional solid dosage form.
1. Introduction
Benzimidazoles (BZD) form a family of related anthelmintic
compounds and their metabolites/derivatives, which are
widely used in antiparasite therapy in both veterinary and
human medicine.
The parent drugs, febendazole (FBZ) and albendazole
(ABZ), contain a sulphur atom as a sulphide at position 5
of the BZD molecule. These sulphides are subjected, mainly
in the liver, to phase I reactions (oxidation), catalysed by
the flavin monooxygenase (FMO) and the cytochrome P-450
(Cyt P-450) enzyme systems to form sulfoxide (SO) metabo-
lites, with FBZSO (oxfendazole; OFZ) and ABZSO being the
primary, pharmacologically active metabolites generated [1,
2]. In a second metabolic reaction (sulphonation), catalysed
by the Cyt P-450 system OFZ and ABZSO are transformed
into inactive sulphone (SO
2
) metabolites, namely, FBZSO
2
and ABZSO
2
, respectively [2].
Several studies have suggested that only limited rates
of dissolution and absorption of BZD anthelmintics are
achieved in cat, dog, and human. Consequently, these com-
pounds may need to be given at higher doses or as multiple
administrations in order to provide adequate therapeutic
concentrations to give an acceptable anthelmintic efficacy [3–
5]. Therefore, new pharmaceutical alternatives are necessary
for increasing the BZD drug exposure to shorten themultiple
administrations. According to the biopharmaceutical classi-
fication system (BCS), ABZ is a BCS class II compound [6]
with an aqueous solubility of less than 5 𝜇g/mL and many
investigations have suggested that dissolution of ABZ is the
rate-limiting step for its absorption [7]. It is thus desirable to
enhance the dissolution rate of the drug in order to increase
its rate of absorption.
The rate at which a solid dissolves is directly proportional
to the surface area of drug exposed to the dissolutionmedium
and is given by the Noyes-Whitney equation [8].
Solid dispersions (SDs), which are defined as molecu-
lar mixtures of poor water-soluble drugs and hydrophilic
carriers, have been proposed as alternatives for improving
the dissolution rate of these kinds of drugs [9], with ABZ
dissolution having previously been assayed at our laboratory
using solid dispersions (SDs) with poloxamer 188 (P 188) as
carrier. Although the proportion of P 188 incorporated in SDs
had a marked influence on ABZ release during the initial
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stage (5min) of the dissolution process.This behaviorwas not
observed for physical mixtures (PMs) of both components.
In this context, the material obtained was characterized for
the dissolution rate of ABZ, and some mechanisms by which
P 188 may act as an efficient carrier in SDs [10] were also
explored. However, after an in vivo assessment in dogs, the
drug plasma exposure of a suspension containing ABZ or
ABZ formulated in a simple solid dispersion (capsules) was
not significantly augmented [11]. The rise in the in vitro
dissolution rate may have been attributed to an increase in
the dissolution surface area, as well as an improvement in
wettability andABZ solubilization as a consequence of carrier
dissolution.
Any favorable effects of P 188 are hidden by the gelation
properties of this material as the temperature is raised [12].
In this way, when solid dispersions are placed in water at
37∘C, gel formation is expected [13–15] which may affect the
kinetic release mainly due to the increase in viscosity. This
fact becomes particularly evident when SDs are vehiculised
into capsule, since compaction is produced as a consequence
of the filling process [9]. It was clear that compaction played
a central role in the potential effectiveness of DSs.
Furthermore, in previous work we have carried out
a pharmacokinetic study in mice using multiparticulate
(uncompacted) DSs and P188 as carrier. An increased sys-
temic availability (𝑃 < 0.001) was obtained when ABZ was
administered as ABZ-P 188 SDs, with a 50% enhancement
in systemic exposure (AUC values) compared to treatment
with an ABZ suspension. Consistently, the Cmax increased
130% (𝑃 < 0.001) following treatment with P 188 based
SD ABZ formulation [16]. In addition, the promising results
concerning the potential effectiveness of SDs based on P
188 for improvement of ABZ Bd and the utility of phar-
macokinetic studies based on mice model for preliminary
screen studies are worthy instead of using superior species
(dogs).
Based on these observations, we hypothesize that the
design of a solid dosage form with a much faster disinte-
gration would prevent or at least minimize any deleterious
gelation effects of P 188 on the ABZ dissolution rate.
Currently, the design and development of rapidly disin-
tegrating tablets (RDTs) is acquiring relevance due to the
advantages of this system, such as easier swallowing and
bioavailability improvement. The design of RDTs is based on
the selection of adequate excipients which allow fast tablet
disintegration (few seconds), even with very low amounts
of water. The key properties of these tablets are the fast
absorption or wetting of water into the tablets and the
disintegration of associated particles into individual compo-
nents for fast dissolution.This requires that excipients should
have a high wettability and the tablet structure should also
have a highly porous network. In order to achieve these
objectives, conventional technologies have been addressed
such as tablet molding, freeze drying, direct compression,
granulation, and spray drying [17]. Likewise, innovative
patented technologies have also been developed. Examples
of these are Zydis, Orasolv, Durasolv, Wowtab, Ceform,
Flashtab, Pharmaburst, Shearform, Ziplet, Oraquick, and
Frosta [18].
In the present study we designed a formulation to use
a marketed coprocessed excipient that had appropriate prop-
erties. In our case, we utilized Ludiflash as the main com-
ponent of the formulae. This material is able to produce a
very fast rupture of the tablet integrity after wetting, with
consequent disintegration of the tablet into fine particles. In
this context, the main objectives of this study were (a) to
evaluate of the performance of the RDTs as a way to improve
the SDs in vitro and (b) to study the in vivo pharmacokinetics
of this ABZ modified formulation in dogs.
2. Materials and Methods
2.1. In Vitro Assessment: Materials. The following materials
were used for the preparation of the solid dispersions: ABZ
(Pharmaceutical grade, Parafarm, Buenos Aires, Argentina)
POLOXAMER 188 (BASF, Germany). All other reagents were
of analytical grade.
For the preparation of tablets, the following excipients
were used: lactose, microcrystalline cellulose, sodium cross-
carmellose, colloidal silicon dioxide, magnesium stearate
(Parafarm, Buenos Aires, Argentina), and Ludiflash (BASF,
Ludwigshafen, Germany).
2.2. Methods
2.2.1. Preparation of Solid Dispersions. SDs were prepared
by melting the carrier (P 188) at 63∘C and with posterior
dispersion of ABZ at 50% w/w. The mixtures were homog-
enized by stirring during heating and dispersion. Then, the
semisolid dispersion was rapidly cooled and pulverized. The
212-micron particle size fraction was obtained by sieving
and was maintained (8∘C) in a screw-capped glass vial until
use.
2.2.2. Development of Solid Dosage Form. The blend of pow-
ders was compressed for 5 s in a hydraulic press (Delfabro,
Argentina) at 1000, 1500, and 2000mPa for conventional
tablets (CTs) and at 250, 500, and 1000mPa for RDTs
with 13.0mm flat punches. Tablet hardness was measured
on recently prepared tablets using an electronic hardness
tester (AVIC, Argentina). Two tablets formulations (Table 1)
containing 200mg of the drug were prepared by direct
compression, with the tableting process, as well as subsequent
storage of the RDT and CTs, taking place in a conditioned
room at 21∘C and 45% RH.
2.2.3. Physical Mechanical Properties
Density and Compressibility. To determine the density of
the powdered blends, the material was gently poured into
a 10 cm3 graduate cylinder, with bulk density (BD) being
calculated as the ratio between the weight (g) and volume
(cm3). To determine the ultimate tap density (TD), the
cylinder was tapped over a 1.0-inch vertical drop, at 1 s
interval, until no measurable change in volume was noticed.
The compressibility of the powder was evaluated using
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Table 1: Components of the rapidly disintegrating tablets (RDTs)
and conventional tablets (CTs).
Ingredients (mg) Rapidly disintegratingtablets
Conventional
tablets
Albendazole — 200
Solid dispersions 400 —
Lactose/Avicel — 25/75
Ludiflash 732 —
Sodium crosscarmellose 60 67.2
Colloidal silicon dioxide — 8
Magnesium stearate 8 16
the Hausner ratio (HR) and Carr’s index (CI) [19] according
to the following equations:
HR = TD
BD
,
CI = TD − BD
TD
× 100.
(1)
Angle of Repose (𝛼). The dynamic 𝛼 for each mixture of
powders was determined by the funnel method as described
in the literature [20].
2.2.4. Dissolution Test. Dissolution tests of RDTs and CTs
were performed using USPXXIV dissolution apparatus 2
(SOTAX AT 7 smart). The rotational paddle speed was set
at 50 rpm, and the temperature remained constant at 37 ±
0.5∘C. The assayed amount of ABZ was 200mg per tablet for
all experiments.
As dissolution medium of 900mL 0.1 N HCl solution
was used, five-milliliter aliquots were withdrawn at prede-
termined time intervals during 1 h, and the same amount
of fresh medium was added in order to keep the volume
constant throughout the test. The samples were filtered, and
the concentration of dissolved drug was measured at 297 nm
using a UV-vis spectrophotometer (Termo Evolution 300).
All measurements were performed in triplicate. In a pre-
vious test, we verified that the presence of carriers dissolved in
the dissolution medium did not affect the 𝜆max of ABZ. The
percentages of dissolved drug were statistically analyzed by
a one-way analysis of variance. Differences were considered
statistically significant at 𝑃 < 0.05.
2.2.5. In Vivo Assessment: Pharmacokinetic Study
(1) Experimental Animals. Six healthy (3–6-year-old) para-
site-free female Retriever dogs, weighing 25–35Kg, were
used in this trial. Whole dogs were fed 12 h before the
treatment and refed 12 h upon treatment. Experimental dogs
were randomly allocated into two groups (𝑛 = 3) (group I:
animals number 1, number 2, number 3; group II: animals
number 4, number 5, number 6), which received two different
treatments using a crossover design. Each experimental
treatment was given to the six animals in two phases: phase
I: animals in Group I received ABZ at 25mg/kg as CTs
(treatmentA). Animals inGroup II received 25mg/kg ofABZ
vehiculized in RDT (treatment B). After 21 days of a wash-
out period, both treatments were reversed and repeated as
phase II.
Blood samples were collected from the antebrachial vein
using a 18G catheter before administration (time 0) and at
0.25, 0.5, 1, 2, 4, 8, 12, 18, and 24 h after the oral adminis-
trations of the respective formulations, before being immedi-
ately transferred into heparinized tubes. Blood samples were
centrifuged at 2000×g for 15min and the recovered plasma
was stored at −20∘C until analysis by HPLC.
(2) Analysis of ABZ and Its Metabolites. Sample cleanup: ABZ,
ABZSO, and ABZSO
2
were extracted using disposable C18
columns. Five microliters of Oxfendazole (OBZ) (5 𝜇g/mL)
was added to 100𝜇L of plasma in a glass test tube. Spiked
samples were placed into a C18 column preconditioned with
0.5mL of methanol followed by 0.5mL water, in a vacuum
system. Samples were washed (2mL of water) and then eluted
with 2mL of HPLC-grade methanol. After elution, all sam-
ples were concentrated to dryness in a vacuum concentrator
and then reconstituted with 150 𝜇L of the mobile phase.
HPLC Analysis. Experimental and spiked plasma samples
(used for validation) were analysed by HPLC using UV
detection.
Chromatography was performed on a Shimadzu HPLC
equipment (Shimadzu Corporation, Kyoto, Japan), provided
with two LC-10AS solvent pumps, an automatic sample
injector (SIL-10A) with a 50 𝜇L loop, an ultraviolet visible
spectrophotometric detector (UV) (SPD-10A) read at 292
nm, a column oven (Eppendorf TC-45, Eppendorf, Madison,
WI, USA) set at 30∘C, and a CBM-10A integrator. Data and
chromatograms were collected and analyzed using the Class
LC10 software (SPD-10A, Shimadzu Corporation, Kyoto,
Japan). The C18 reversed-phase column (5 𝜇m, 250mm ×
4.6mm) was obtained from Kromasil (Kromasil, Sweden).
Elution from the stationary phase was carried out at a flow
rate of 1.2mL/min using acetonitrile (40%) and a potassium
phosphate buffer (25mM, pH 5.3, 40%) as the mobile phase.
Fifty microliters of each sample was injected, and the
analytes were eluted from the analytical column (5 𝜇m,
250mm × 4.6mm, C18 column) using a linear gradient
method as reported by Sa´nchez et al. [21]. The compounds
were identified by the retention times of standard references.
Plasma calibration curves for each analyte were constructed
by a least squares linear regression analysis, which gave a
correlation coefficient (𝑟) of between 0.9987 and 0.9995. The
limits of quantification were 0.01𝜇g/mL (ABZ and ABZSO)
and 0.03 𝜇g/mL (ABZSO
2
).
Pharmacokinetic Analysis of the Data.The concentration ver-
sus time curves for the metabolites ABZSO and ABZSO
2
in
plasma for each individual animal after the different treat-
ments were fitted using PK Solution 2.0 (Summit research
services, Ashland, OH, USA). The following equation [22]
was used to describe the biexponential concentration-time
curves for ABZSO and ABZSO
2
after the oral treatment:
𝐶
𝑝
= 𝐵𝑒
−𝜆
2
⋅𝑡
− 𝐵𝑒
−𝜆
1
⋅𝑡
, (2)
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Table 2: Physical-mechanical characterization of the formulations: Bulk density (BD), Tap density (TD), Carr’s index, Hausner ratio, and
angle of repose.
Angle of repose (∘) Carr’s index (%) Hausner Ratio (%) TD (m/v) BD (m/v)
Conventional tablets 39 ± 2 16.6 1.2 0.6 ± 0.02 0.5 ± 0.1
Rapidly disintegrating tablets 38.9 ± 1.65 22.22 1.28 0.63 ± 0.02 0.49 ± 0.01
Table 3: Values of hardness and disintegration time for both formulations at different compaction forces.
Compaction force (mPa) Hardness (kg/cm2) Disintegration time (min.)
Conventional tablets
1000 4 ± 1 5.5
1500 11 ± 1 12
2000 18 ± 3 15
Rapidly disintegrating tablets
250 3 ± 0.5 2.5
500 4 ± 0.5 2.5
1000 8 ± 2 2.7
where 𝐶
𝑝
is concentration in plasma at time 𝑡 after adminis-
tration (𝜇g/mL); 𝐵 is concentration at time zero, extrapolated
from the elimination phase (𝜇g/mL); 𝑒 is base of the natural
logarithm; 𝜆
2
is terminal slope (h−1); and 𝜆
1
is the slope
obtained by feathering, which represents either the first-order
absorption rate constant (𝜆
1
) or the first-order metabolite
formation rate constant (𝜆for) (h
−1). The elimination half-life
(𝑡
1/2
𝜆
2
) and absorption (𝑡
1/2
𝜆
1
) or the metabolite formation
half-lives (𝑡
1/2
𝜆for) were calculated as ln 2/𝜆2 and ln 2/𝜆1,
respectively.
The peak concentration (𝐶max) and time to peak concen-
tration (𝑇max) were obtained from the plotted concentration-
time curve of each analyte.The area under the concentration-
time curve (AUC) and the area under the first moment curve
(AUMC) were calculated by the linear trapezoidal rule [23]:
AUMC
(0−∞)=
𝑛−1
∑
𝑖=0
𝑡
𝑖+1
− 𝑡
𝑖
2
(𝑐
𝑖
𝑡
𝑖
+ 𝑐
𝑖+1
𝑡
𝑖+1
)(
𝐶last ∗ 𝑡last
𝜆
𝑧
+
𝐶last
𝜆2
𝑧
).
(3)
Statistical Analysis of the Data. The nonparametric Mann-
Whitney test was used for themultiple statistical comparisons
of the PK data obtained from the different groups. A value of
𝑃 < 0.05 was considered to be statistically significant.
3. Results and Discussion
Powder blends easily compacted bymeans of direct compres-
sion should possess good flow and compression properties.
The rheological properties of powder blends were assayed
by evaluation of density, angle of repose, and compressibility
(Hausner ratio). The Hausner ratio and Carr’s index refer
to the packing characteristics of the materials and therefore
can be used as indicators of powder flowability. For both
RDT and CT formulations, the results (Table 2) showed that
the powders possessed suitable rheological properties and
compressibility. The hardness, disintegration, and friability
of the compacts were also evaluated for each formulation
(Table 3) because tablet disintegration as well as drug dis-
solution is relevant, with both being closely related to the
expected biopharmaceutical performance of the formulation.
As expected, the disintegration time was shorter in the case
of RDTs in comparison to the CTs. This may have been
attributed to the incorporation of Ludiflash into the formulae,
which was then able to produce water uptake, swelling, and
quick rupture of the compact. For both formulations and for
all the compaction forces, the friability was less than 1%.
Regarding the compression behaviour, the influence of
compaction forces (CF) on the hardness and the disintegra-
tion time of the compact was analysed. When the CF was
raised, an increase of the hardness in the tablets was observed,
as expected.This was remarkable when CTs were considered,
due to the presence of Avicel, which is a very compressible
material.
The in vitroABZ dissolution profiles are shown in Figures
1(a) and 1(b). In particular the RDTs dissolution rate was not
affected by increasing the CF, when tablets were compacted at
250 and 500mPa. However, at 1000mPa a slower dissolution
rate was visualized, which was a consequence of the observed
enhancement of the disintegration time. The CTs compacted
at 1000MPa showed the fastest dissolution rate, as observed
in Figure 1(b).
From these results, and based on the lower hard-
ness/disintegration and faster dissolution rate, CTs com-
pacted at 1000mPa and RDTs compacted at 500mPa were
selected as the model formulations for further in vivo
bioavailability studies.
Differences in the pharmacokinetic profiles of benzimi-
dazoles (BZD) anthelmintics have been reported, depending
on the animal species. Anatomic features influence the
passage of digesta and the bioavailability, so the pharmacoki-
netics of anthelminticsmay be affected by different gut transit
features [24]. ABZ parent drug was not detected in plasma,
being the detection of the metabolite ABZSO (also named
ricobendazole) as the main molecule with antiparasitic activ-
ity in bloodstream. In dogs, the plasma concentrations and
the mean residence times of ABZ and their sulfoxide and
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Figure 1: Dissolution profile: (a) rapidly disintegrating tablets (RDTs) and (b) conventional tablets (CTs) at different compaction forces:
F250: compaction forces a 250mPa; F500: compaction forces a 500mPa; F1000: compaction forces a 1000mPa; F1500: compaction forces a
1500mPa; F2000: compaction forces a 2000mPa.
sulphone metabolites are lower and shorter, respectively, in
comparison to in ruminant species on human [25]. This may
be explained by the fact that there exists a relatively short
transit time in the gastrointestinal tract of dogs compared to
other animal species.
According to various reports, the absorption of BZD
anthelmintic drugs in cats, dogs, and humans is substantially
limited by their low dissolution rates in gastric fluids [26, 27].
Consequently, these compounds must be administrated at
high doses or as multiple doses in order to provide sustained
concentrations at the parasite site. It is well known that the
incorporation of low-solubility drugs into solid dispersions
(SDs) is an effective alternative for increasing the in vitro
dissolution rate. In this paper, we improved this property
in ABZ by obtaining a solid dispersion compounded by
ABZ : P 188 (1 : 1) [8], with an increase being observed in
the dissolution assays when solid dispersions were poured as
powder onto the dissolution media surface. However, when
SDs were put into capsules, the corresponding dissolution
test showed that the capsules were not able to improve the
dissolution rate [9].
As a consequence of the thermal gelation properties of
P 188, the partially compacted powder absorbed water pro-
duced swelling and gel formation and an increase in gel
viscosity due to the rise of temperature (37∘C). However, this
behavior was practically negligible when SDs were manipu-
lated as a bulk powder in similar conditions. In a previous
work, carried out on mice, we observed a significant increase
in the bioavailability when solid dispersions were adminis-
tered orally as a multiparticulate system (thus avoiding the
effects of compaction) compared to ABZ suspension [28].
From these results and considering that the formulation
of a tablet may imply a compaction process that decisively
affects the dissolution rate, we investigated the incorporation
of ABZ solid dispersion in the RDTs (treatment B), as a
viable alternative for avoiding or minimizing adverse effects.
Therefore, the formulation with ABZ incorporated in CTs
(treatment A) was studied for its effect on the bioavailability
in dogs (Figures 2 and 3, Table 4).
In our case, the results obtained in vitro were reflected in
the in vivo studies.
As reported in other studies, after both treatments the
ABZ parent drug was not detected in the plasma, but ABZSO
was detected in plasma at 18 h and 24 h after treatment
(treatments A and B, respectively). This ABZSO plasma
disposition (AUC) was significantly greater (1.6-fold more at
𝑃 < 0.05) after treatment B compared to treatment A. This
same trend was observed for parameter 𝐶max after treatment
B, where the concentration obtained was 1.5-fold higher
compared with treatment A (𝑃 < 0.05). A nonsignificant
delay in 𝑇max. was present after treatment B (7.2 h) compared
with treatment A (6 h) (see Table 4 and Figure 2).
Modifications of the pharmacokinetic parameters were
reflected in an improvement of the dissolution rate as a
consequence of the rapid disintegration of the RDTs, which
produced a remarkable increase in kinetic absorption as
well as in the drug amount available in the plasma. The
RDTs were able to disintegrate in only a few seconds after
administration, allowing the resulting fine solid dispersion
to reach the stomach where the rapid dissolution of solids
may occur. In contrast, each solid particle compacted in
CTs was very difficult to be accessed by the solvent, and a
process of swelling and gelation began. Thus, the gel layer
formed prevented the particle from being wetted and resulted
in disintegration and drug dissolution. This delay in the
ABZ dissolution process was especially deleterious for ABZ
bioavailability, since it has to dissolve rapidly along the short
length of the dog’s gastrointestinal tract.
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Table 4: Comparative plasma disposition kinetic variables for albendazole sulfoxide (ABZSO) and albendazole sulphone (ABZSO2) after the
oral administration of three different formulations.
Pk parameters Group I (ABZ control) conventional tablets Group II Rapidly disintegrating tablets
ABZSO ABZSO2 ABZSO ABZSO2
𝑇
1/2 abs. (h) 2.14 ± 1.28 2.46 ± 1.81 2.38 ± 0.42 4.93 ± 1.81
𝑇max (h) 6.00 ± 2.31 7.13 ± 4.80 7.20 ± 1.79 12 ± 0.00
𝑇
1/2 elim. (h) 4.67 ± 1.68 32.13 ± 39.63 4.73 ± 1.19 10.86 ± 7.47
𝐶max (𝜇g/mL) 5.33 ± 2.83 0.67 ± 0.27 8.18
∗
± 1.47 1.13 ± 0.34
AUC
0–∞ (𝜇g⋅h/mL) 52.20 ± 12.95 33.32 ± 46.20 113.11
∗
± 22.85 22.32 ± 10.33
AUMC
0–∞ (𝜇g⋅h
2/mL) 718.50 ± 274.17 222.56 ± 149.04 1180.30 ± 306.44 382.18 ± 344.47
MRT (hr) 12.11 ± 3.99 49.76 ± 56.09 10.48 ± 1.78 21.71 ± 10.90
PDP (h) 0.25–24.0 0.25–24.00 0.25–24.0 0.25–24.0
𝑇1/2 abs.: metabolite formation half-life, 𝐶max: peak concentration, 𝑇max: time at 𝐶max, 𝑇1/2 elim.: elimination half life, AUC0–∞: area under the concentration
versus time curve extrapolated to infinity, AUMC0–∞: area under the moment of the concentration versus time curve extrapolated to infinity, MRT: Mean
residence time, and PDP: plasma detection period. (∗) values are statistically different to group I at P < 0.05.
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Figure 2: Comparative (mean ± SD) plasma profiles for albenda-
zole sulfoxide (ABZSO) after the administration of two different
oral-based albendazole (ABZ) formulations: rapidly disintegrating
tablets (RDTs) and conventional tablets (CTs).
4. Conclusions
The bioavailability of ABZ from SD compacted in tablets
was extremely conditioned by the initial dissolution rate.
A tablet design based on fast disintegrating excipients was
shown to be more successful in increasing the absorption
process compared with traditional tablets. Therefore, rapid
disintegration of tablets seems to be a key factor for efficiency
of SD with regard to improvement of the ABZ bioavailability.
The in vivo assays performed on dogs showed a marked
increase in drug plasma exposure when ABZ was given in SD
incorporated into RDTs compared with CTs. This behavior
allowed us to deduce that a positive and direct correlation
existed between the in vitro dissolution rate and the expected
pharmacokinetic of ABZ. Although SD was demonstrated to
be an efficient strategy for improving the dissolution rate, a
correct formulation of the tablet was necessary in order to
guarantee that the disintegration process was not a limiting
step in the ABZ absorption. This formulation may have
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Figure 3: Comparative (mean ± SD) plasma profiles for albenda-
zole sulphone (ABZSO
2
) after the administration of two different
oral-based albendazole (ABZ) formulations: rapidly disintegrating
tablets (RDTs) and conventional tablets (CTs).
a beneficial impact by shortening the antiparasite therapy
time needed in monogastrics.
Appendix
Animal procedures and management protocols were ap-
proved by the Ethics Committee according to the Animal
Welfare Policy (act 087/02) of the Faculty of Veterinary
Medicine, Universidad Nacional del Centro de la Provincia
de Buenos Aires (UNCPBA), Tandil, Argentina (http://www
.vet.unicen.edu.ar/).
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